Hardy TS Kagimoto,
Founder, Chairman and CEO
Hardy TS Kagimoto, MD is founder, Chairman and CEO of HEALIOS K.K., a Tokyo-based, clinical-stage world leader in regenerative medicine and cell therapy.
After founding Healios in 2011, Dr. Kagimoto led the company’s listing on the Tokyo Stock Exchange in 2015. Healios leverages the favorable Japanese regulatory framework for regenerative medicine to efficiently deliver results for patients and its stakeholders. Healios is developing best-in-class, next generation pipeline assets in immuno-oncology, ophthalmology, and organ buds utilizing its innovative, proprietary universal donor iPS cell platform. In addition, it conducted two pivotal clinical trials for ischemic stroke and acute respiratory distress syndrome using bone marrow-derived allogeneic multipotent adult progenitor cells.
Dr. Kagimoto is a Kyushu University hospital trained medical doctor. Prior to founding Healios, he built and ran his first biotech company, Aqumen, and launched BBG250 which gained global de-facto-standard status as a surgical adjuvant in the ophthalmology community.
|
|
|
